Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Numbing injection may slash opioid pills needed after rhinoplasty

NCT ID NCT06989866

First seen Nov 01, 2025 · Last updated Jun 21, 2026 · Updated 36 times

Summary

This study tests whether a numbing injection (bupivacaine) given after nose surgery can reduce the number of strong pain pills patients need. Fifty adults having primary septorhinoplasty will be randomly assigned to receive either the numbing shot or a placebo. Researchers will track how many opioid pills are used and measure pain levels for a week.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for POSTOPERATIVE PAIN are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Naval Medical Center Portsmouth

    Portsmouth, Virginia, 23708, United States

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Bupivacaine (a numbing medicine)

What this could lead to

If it works, this could offer a way to manage post-surgery pain with fewer opioid pills, reducing the risk of dependence and side effects.

What could go wrong

This is a small, early-phase trial with only 50 participants, so results may not apply to everyone. The numbing effect may not be strong enough to replace opioids for all patients.

Conditions

The condition(s) this trial relates to.

Pain, Postoperative

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.